Tohope Pharmaceutical

Tohope Pharmaceutical is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative therapies for metabolic diseases and oncology. The company's primary focus is on multi-agonist peptide drugs targeting the GLP-1, GIP, and glucagon receptors to treat conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Its lead programs, including THP-1814 and THP-1815, are currently undergoing clinical evaluation to demonstrate superior efficacy in weight loss and glycemic control. Tohope leverages its internal R&D capabilities to advance a diverse pipeline of next-generation biologics and small molecules. The company aims to address significant unmet medical needs in the global metabolic health market through precision drug design.